Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS (omburtamab), which targets tumors that express B7-H3. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb) that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. Omburtamab is a novel murine monoclonal antibody designed for compartmental immunotherapy. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several types of cancers, including pediatric CNS/LM from NB.